Swiss pharma giant Novartis’ Cosentyx (secukinumab) is to be made available on the National Health Service (NHS) in England and Wales for another condition affecting a major patient group.
Cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has published a positive final appraisal determination (FAD) recommending the use of Cosentyx alone or in combination with methotrexate in active and progressive psoriatic arthritis (PsA).
"A growing body of evidence supports the potential of secukinumab to become the standard of care for patients living with this debilitating condition"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze